Get started
Sage Therapeutics, Inc.Sage Therapeutics, Inc.Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SAGE chart


Full chart

SAGE upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪456.80 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.60 USD
Net income (FY)
‪−400.67 M‬ USD
Revenue (FY)
‪41.24 M‬ USD
Shares float
‪54.08 M‬
Beta (1Y)
1.67

Employees


Employees (FY)
353
Change (1Y)
−134 −27.52%
Revenue / Employee (1Y)
‪116.84 K‬ USD
Net income / Employee (1Y)
‪−1.14 M‬ USD

About Sage Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Barry E. Greene
Website
sagerx.com
Headquarters
Cambridge
Founded
2010
FIGI
BBG0025X16Y5
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SAGE news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as SAGE.

Frequently Asked Questions


The current price of SAGE is 7.43 USD — it has increased by 0.81% in the past 24 hours. Watch Sage Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sage Therapeutics, Inc. stocks are traded under the ticker SAGE.
SAGE stock has risen by 9.59% compared to the previous week, the month change is a −6.66% fall, over the last year Sage Therapeutics, Inc. has showed a −42.67% decrease.
We've gathered analysts' opinions on Sage Therapeutics, Inc. future price: according to them, SAGE price has a max estimate of 12.00 USD and a min estimate of 5.00 USD. Watch SAGE chart and read a more detailed Sage Therapeutics, Inc. stock forecast: see what analysts think of Sage Therapeutics, Inc. and suggest that you do with its stocks.
SAGE reached its all-time high on Jan 31, 2018 with the price of 195.97 USD, and its all-time low was 4.62 USD and was reached on Nov 20, 2024. View more price dynamics on SAGE chart.
See other stocks reaching their highest and lowest prices.
SAGE stock is 2.80% volatile and has beta coefficient of 1.67. Track Sage Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sage Therapeutics, Inc. there?
Today Sage Therapeutics, Inc. has the market capitalization of ‪456.80 M‬, it has increased by 8.96% over the last week.
Yes, you can track Sage Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Sage Therapeutics, Inc. is going to release the next earnings report on Apr 29, 2025. Keep track of upcoming events with our Earnings Calendar.
SAGE earnings for the last quarter are −1.56 USD per share, whereas the estimation was −1.48 USD resulting in a −5.17% surprise. The estimated earnings for the next quarter are −0.98 USD per share. See more details about Sage Therapeutics, Inc. earnings.
Sage Therapeutics, Inc. revenue for the last quarter amounts to ‪12.81 M‬ USD, despite the estimated figure of ‪14.37 M‬ USD. In the next quarter, revenue is expected to reach ‪14.12 M‬ USD.
SAGE net income for the last quarter is ‪−95.78 M‬ USD, while the quarter before that showed ‪−93.55 M‬ USD of net income which accounts for −2.38% change. Track more Sage Therapeutics, Inc. financial stats to get the full picture.
No, SAGE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 20, 2025, the company has 353 employees. See our rating of the largest employees — is Sage Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sage Therapeutics, Inc. EBITDA is ‪−408.89 M‬ USD, and current EBITDA margin is −992.86%. See more stats in Sage Therapeutics, Inc. financial statements.
Like other stocks, SAGE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sage Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sage Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sage Therapeutics, Inc. stock shows the sell signal. See more of Sage Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.